Downloadable Resources

Professional resources

Dosing and Administration Guide

  • A guide to treating patients with BESPONSA including dose preparation, administration, and storage

Download

An Overview of Clinical Data, Product Information, and Patient Monitoring & Counseling

  • A summary of BESPONSA efficacy and safety outcomes along with product preparation and patient guidance

Download

expert view

Expert Review: BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

  • Dr Olalekan Oluwole presents a review of ALL treatment with BESPONSA, including clinical outcomes, VOD risk factors, and 2 patient cases

Download

Clinical publications

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

  • Expert panel recommendations on monitoring and managing VOD and other AEs associated with BESPONSA (open access)

Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456. doi:10.1038/s41409-017-0019-y

Download

Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia

  • An exploratory analysis of post-HSCT clinical outcomes for both BESPONSA and standard chemotherapy (open access)

Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720-1729. doi:10.1016/j.bbmt.2019.04.020

Download

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

  • An analysis of the predictive value of MRD negativity following treatment with BESPONSA (open access)

Jabbour E, Gökbuget N, Advani A, et al. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020;88:106283. doi:10.1016/j.leukres.2019.106283

Download

AE=adverse event; ALL=acute lymphoblastic leukemia; HSCT=hematopoietic stem cell transplantation; MRD=measurable residual disease; VOD=veno-occlusive disease.

Reference
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 26, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.